

AD _____

Award Number: DAMD17-03-1-0066

TITLE: Biochemical Markers of Brain Injury: An Integrated Proteomics-Based Approach

PRINCIPAL INVESTIGATOR: Ronald L. Hayes

CONTRACTING ORGANIZATION: University of Florida
Gainesville, FL 32610

REPORT DATE: February 2007

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-02-2007		2. REPORT TYPE Final		3. DATES COVERED 1 Feb 2003 – 31 Jan 2007	
4. TITLE AND SUBTITLE Biochemical Markers of Brain Injury: An Integrated Proteomics-Based Approach				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-03-1-0066	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Ronald L. Hayes Email:				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Florida Gainesville, FL 32610				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white.					
14. ABSTRACT Brain injury poses a major problem to military care. Historically brain injury has accounted for 25% of all combat casualties and is the leading cause of death among wounded soldiers reaching Echelon I medical treatment. Recent experience in Iraq has suggested brain injury may make an even greater contribution to combat casualties. Incidence of brain injury and resultant long-term disabilities caused by traumatic insults and ischemic events is significantly greater in the civilian population. No clinically useful diagnostic tests exist for traumatic or ischemic brain injury to provide physicians with quantifiable neurochemical markers to help determine the seriousness of the injury, the anatomical and cellular pathology of the injury and to guide implementation of appropriate triage and medical management. Study Design: SOW 1 employs integrated proteomics-based technologies to identify specific proteins or peptide fragments in brain released into CSF and/or blood of rats following experimental traumatic brain injury or focal cerebral ischemia. Technologies include mass spectroscopy, 2-D gelelectrophoresis, phage display of single chain antibodies and antibody chips. SOW 2 employs antibody chips to determine which proteins or peptide fragments released into CSF following injury are reliably associated with different injury magnitudes and predict changes in histopathological, behavioral and electrophysiological outcome measures. SOW 3 develops ELISA-based assays capable of detecting biomarkers in blood. Relevance: Development of "objective triage" capabilities for combat medics and/or Echelon I providers would represent a major "fieldable" breakthrough in the medical management of combat related head trauma.					
15. SUBJECT TERMS Brain injury					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	23	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	17
Reportable Outcomes.....	18
Conclusion.....	23
References.....	N/A
Appendices.....	N/A

INTRODUCTION

Recent combat experiences in Iraq have highlighted the fact that traumatic brain injury (TBI) is one of the most frequent causes of mortality and morbidity on the modern battlefield. More than half of combat casualties in Iraq may suffer from TBI. Forty percent of battlefield fatalities in Viet Nam were due to head wounds. It has also been reported that of patients arriving alive at military field hospitals, 20% with severe brain wounds die before surgery is performed, and 80% receive neurosurgical treatment with a 10% surgical mortality rate. Penetrating head injury alone accounts for 25% of all war time casualties and approximately 40% of these injuries are fatal. Thus, the current proposal focuses on the ultimate development of non-invasive diagnostics (i.e., biomarkers) of TBI that ultimately will be useful in a battlefield environment. The research has been divided into 3 SOWs reviewed below.

As summarized in the body of this final report, we have made significant progress over the funding period of this proposal and are poised to expand our technology to the study of penetrating ballistic brain injury. This research has established the preclinical infrastructure to improve diagnosis of TBI.

SOW 1: To employ integrated proteomics-based technologies to identify specific proteins or peptide fragments in brain released into CSF and/or blood of rats following experimental TBI or focal cerebral ischemia (middle cerebral artery occlusion: MCAO).

(A) Conduct concurrent studies employing mass spectrometry (HPLC MALDI-TOF protein profiling's Isotope-coded affinity tags-ICAT), 2D-gel electrophoresis, and phage display of single chain antibodies to detect proteins or peptide fragments in brain and CSF after TBI or MCAO.

(B) Employing injury-related proteins or peptide fragments identified in SOW 1-A, construct and validate the sensitivity of an antibody chip. Validation of the chip would on focus studies in CSF but would also explore chip utility for blood analyses.

SOW 2: Employing the antibody chip developed in SOW 1-B, determine which protein or peptide fragments released into CSF following TBI or MCAO are reliably associated with different injury magnitudes and predict changes in histopathological, behavioral and electrophysiological outcome measures.

(A) CSF will be sampled at multiple time points following injury to determine the optimal sampling time(s) predictive of injury magnitudes. If feasible based on data from SOW 1-B, limited studies will be conducted employing blood samples. (Months 25-30).

(B) Using the same injury magnitudes and data on release of protein or peptide fragments derived from the antibody chips employed in SOW 2-A, identify which sampling time(s) and which protein or peptide fragments released into CSF are optimally predictive of histopathological behavioral or electrophysiological assessments of outcome following TBI or MCAO. EEG analyses of electrophysiological alterations will be conducted following TBI and ischemia. Histopathology will be assessed by hematoxylin and eosin (H&E) staining for TBI and triphenyltetrazolium chloride (TTC) staining for MCAO. Behavioral assessments will include Morris water maze and Rotorod assessments following TBI and neurological examinations and forelimb sensorimotor assessments following MCAO.

SOW 3:

(A) Develop highly sensitive, quantitative ELISA-based assays capable of detecting blood levels of protein or peptide fragments determined to be optimally predictive of injury magnitude and outcome in SOW 2.

(B) Conduct preliminary validation of the utility of ELISA based assays employing blood samples taken following brain injury.

BODY

In our initial studies conducted in this proposal, we confirmed that accumulation of calpain and caspase-3 proteolytic fragments of brain derived α II-spectrin accumulate in CSF after middle cerebral artery occlusion (MCAO) in rats (**Pike et al., JCBFM, 2004**). This investigation confirmed previous studies in TBI that accumulation of calpain and caspase-3-cleaved- α II-SBDPs accumulate in CSF of rodents following MCAO. Following MCAO injury, full length α II-spectrin protein was decreased in brain tissue and increased in CSF. Calpain and caspase-3 α II SBDPs were also increased in brain and CSF after injury. Levels of these proteins were undetectable in CSF of uninjured control rats. These results indicate that calpain and caspase-3 cleaved α II SBDPs in CSF may be useful diagnostic indicators of cerebral infarction that could provide important information about specific neurochemical events that occur in the brain after acute stroke. In addition, these data confirm that similar profiles occur following stroke as well as TBI.

We have 2 important reviews that are of relevance to investigators developing biomarkers for acute CNS injury. The first review summarizes the status of research on biomarkers of proteolytic damage following TBI (**Pineda, et al, in press**). The second review (**Denslow, et al, J Neurotrauma, 2003**) provides an important resource for application of proteomics technology to the study of acute CNS injury. These 2 reviews confirm the leading role our research laboratory is taking in this new and important field.

In other earlier research in this proposal we conducted extensive studies of the utility of CSF levels of α II-spectrin breakdown product levels as markers of TBI. These extensive studies represent systematic efforts to conduct preclinical assessments of the ultimate clinical utility of these biomarkers in humans (**Ringger et al., J Neurotrauma, 2004**). Currently, there is no definitive diagnostic test for TBI to help physicians determine the seriousness of injury or the extent of cellular pathology. Calpain cleaves α II-spectrin into breakdown products (SBDP) after TBI and ischemia. Mean levels of both ipsilateral cortex (IC) and cerebral spinal fluid (CSF) SBDP at 2, 6 and 24 h after 2 levels of controlled cortical impact IC SBDP levels are significantly higher after severe (1.6 mm) injury than mild (1.0 mm) injury over time. The correlation between CSF SBDP levels and lesion size from T2-weighted magnetic resonance images 24 hrs after TBI as well as correlation of tau and S100B was assessed. Mean levels of CSF SBDP ($r = 0.833$) significantly correlated with lesion size while levels of CSF S100B did not ($r = 0.188$). Although levels of CSF and IC SBDP and lesion size are all significantly higher after 1.6 mm than 1.0 mm injury, the correlation between CSF SBDP and lesion size was not significant following the removal of controls from the analysis. This indicates CSF SBDP is a reliable marker of the presence or absence of injury. Furthermore, larger lesion sizes 24 hrs after TBI were negatively correlated with motor performance on days 1-5 after TBI ($r = -0.708$). Based on these data, evaluation of CSF SBDP levels as a biomarker of TBI is warranted in clinical studies.

An important component of the proposal was to develop proteomics based platforms for discovery of novel biomarkers of TBI. We have recently outlined our proteomics-based strategy and its successful application (**Wang, et al., International Review of Neurobiology, 2004**). With the completion of human and rat genomes, the next major technological challenge facing the biomedical community is the deciphering of the human proteome. Study of the proteome has been aided by recent advances in protein separation, protein identification/quantification, and bioinformatics. Although the application of proteomics technologies in brain injury research is still in its infancy, enormous insights can be achieved from such endeavors. There are approximately 30,000-40,000 hypothetical protein products transcribable from the human genome (**Aebersold and Watts, 2002; Grant & Blackstock, 2001; Grant & Husi, 2001; Hanash, 2003; Hochstrasser et al., 2002; Service, 2001; Smith, 2000**). Yet, the proteome is extremely complex. Even in a single cell type the set of proteins that are expressed, as well as their steady state levels, depend on time and the specific state of the cells in response to environmental stimuli or challenges. In addition, cellular proteins are almost constantly subjected to various forms of post-translational modifications (PTMs), including phosphorylation/dephosphorylation by different kinases and phosphatases, proteolysis, or processing by different protease families, acetylation, glycosylation, and cross linking by transglutaminases or conjugation to small protein tags such as ubiquitin or SUMO (similar to ubiquitin modifier: Janssen, 2003, Schafer et al., 2003; Schwartz

and Hochstrasser, 2003). Because of these challenges, one often has to focus on a specific subproteome. The case in point is neuroproteomics, or the study of nervous system proteomes. The importance of neuroproteomics studies is that they will help elucidate the poorly understood biochemical mechanisms or pathway that currently underlie various psychiatric, neurological and neurodegenerative diseases.

We have made important methodological advances to facilitate rapid discovery of putative protein biomarkers of TBI (**Haskins et al., J Neurotrauma, In Press**). We report the rapid discovery of putative protein biomarkers of TBI by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry (SDS-PAGE-Capillary LC-MS²). Ipsilateral hippocampus (IH) samples were collected from naïve rats and rats subjected to controlled cortical impact (a rodent model of TBI). Protein database searching with 15,558 uninterpreted MS² spectra, collected in 3 days via data-dependent Capillary LC-MS² of pooled samples separated by SDS-PAGE, identified more than 306 unique proteins. Differential proteomic analysis revealed differences in protein sequence coverage for 170 mammalian proteins (57 proteins in naïve only, 74 protein in injured only, and 39 proteins in both), suggesting that some of these proteins are putative biomarkers of TBI. Confidence in our results was obtained by the presence of several known biomarkers of TBI, (including α II-spectrin, brain creatine kinase, and neuron-specific enolase) in our data set. Sequence-specific discovery of putative protein biomarkers (by data-dependent Capillary LC-MS²) and preliminary validation of selected biomarkers (by targeted Capillary LC-MS²), show that SDS-PAGE prior to *in vitro* proteolysis and Capillary LC-MS² is a promising strategy for the rapid discovery of putative protein biomarkers associated with a specific pathophysiological state (i.e., TBI) without *a priori* knowledge of the molecules involved.

We have importantly expanded our search for biochemical markers of acute CNS injury. Consistent with our focus on examining proteolytic mechanisms of damage, we have examined the role of cathepsin B mRNA and protein expression following contusion spinal cord injury (**RC Ellis et al., J Neurochem., 2004**). These studies lay the foundation for future research in TBI. We provide the first data that cathepsin B (Cath B), a lysosomal cysteine protease, is upregulated following contusion spinal cord injury (SCI). Following T12 laminectomy and moderate contusion, Cath B mRNA and protein expression profiles were examined from 2 to 168 hrs post-injury in rats using real-time PCR and immunoblots, respectively. Contusion injury significantly increased mRNA Cath B in the injury site and adjacent segments over sham injury levels. While the largest mRNA Cath B induction (20-fold over naïve) was seen in the injury site, the caudal segment routinely yielded mRNA Cath B levels greater than 10-fold over naïve. Interestingly, sham injury animals also experienced mRNA induction at several time points at the injury site and in segments rostral and caudal to the injury site. Contusion injury also significantly elevated levels of Cath B proenzyme protein (37 kDa) over sham injury in the injury site (48, 72 and 168 hrs post-injury). Furthermore, significant protein increases of single and double chain Cath B (both active forms) occurred at the injury site at 72 and 168 hrs post-injury. Similar significant increases in Cath B protein levels were seen in areas adjacent to the injury site. The induction of Cath B mRNA and protein expression following contusion injury is previously undescribed and suggests that Cath B may potentially be involved in the secondary injury cascade, perhaps for as long as 1 week post-injury.

In the previous year we significantly expanded our non-targeted biomarker discovery efforts, building on last year's success in characterizing injury magnitude and progression using a select set of markers (e.g., α II-spectrin) in animal and clinical samples. Our contention has been that an array of TBI biomarkers will be most effective as a diagnostic assay. To this end, it was imperative that we identify as many protein markers as possible. We explored two complimentary high-throughput proteomics approaches for biomarker discovery, (1) bioanalytical mass spectrometry and (2) high-throughput protein immunoblotting (HTPI). Both approaches are capable of detecting thousands of proteins, and are useful in identifying protein changes between control and injured tissues.

Mass spectrometry has exploded into the area of protein chemistry over the last five years. Methodology involves the separation of proteins from complex biological samples, isolating differences between control and injured proteins, and identifying the different proteins using mass spectrometry analysis. The challenge to this approach is in the numbers – there are thousands of proteins in a brain sample differing in their abundance over a 9-order magnitude range. Further, mass spectrometry requires

that all proteins be broken up into smaller peptide fragments, increasing sample complexity 100-fold. Our first approach incorporated the use of differential cyanine dyes and SDS-PAGE protein separation (**Figure 1**). Protein bands that appeared different in abundance between samples stood out against an otherwise yellow background when the red and green images were superimposed. These highlighted differences could then be excised from adjacent gel lanes containing separate naïve and TBI tissue. Differences could then be excised from adjacent gel lanes containing separate naïve and TBI tissue.




Figure 1. Differential protein analysis using cyanine dyes and SDS-PAGE. Tissue lysate from injured and naïve samples were differentially labeled with cyanine dyes and loaded onto a gel next to lanes where each sample was loaded separately. Differential proteins were identified in the dye lane as a red or green band. Adjacent gel slices were excised from the injured / naïve only lanes for mass spectrometry analysis

Using this approach we were able to identify over 300 proteins, 57 in naïve only and 74 in injured only (**Haskins et al., J. Neurotrauma 2005**); however, we had difficulties determining which exact protein was the differential protein we observed with the cyanine dyes. The difficulty arose when correlating the large number of proteins identified the adjacent naïve or injured gel lanes with the single differential band observed in mixed-sample cyanine dye lane. What we determined is a) that differential protein analysis must be performed using the lanes of the separate naïve and injured samples and b) that additional protein separation was required for reducing the complement of proteins identified in a single excised gel band.

Following the above study, we explored using two-dimensional gel electrophoresis (2D-PAGE), the standard for high-resolution protein separation. We immediately faced the common problem of poor gel-to-gel reproducibility, which limited our ability to perform differential protein analysis. Cyanine fluorophores have been touted as a method for avoiding reproducibility problems, but would require mixing the naïve and injured sample on the gel, reminiscent of the problems we ran into with our first mass spectrometry study. We then opted to develop a new differential analysis platform that could be reliable for comparing two or more samples but would provide high-resolution separation like that of 2DPAGE. Our answer is a method that involves ion-exchange chromatographic separation of each sample into multiple fractions and resolution of those fractions by 1-dimensional gel electrophoresis. The key to this approach is that fractions for each sample are paired up (i.e., fraction 1 control next to fraction 1

injured, etc.) and run side-by-side on the sample gel, thereby avoiding issues with gel-to-gel reproducibility. Likewise, we are able to maintain proteins from each sample separately, and can easily compare band density values between adjacent lanes. We were also able to false-color the separate gel lanes for a superimposed color image resembling that of the cyanine dyes for easy manual band decoding (**Figure 2**). However, in practice it was more efficient to use gel analysis software to find differential protein bands between lanes.




Figure 2. High-resolution protein separation of naïve and injured brain samples. Overlay of false colored naïve and injured protein fractions following novel 2D protein separations indicates proteins of varying abundance following TBI.

We have determined that this approach is comparable in protein resolving capability to that of 2D-PAGE, but provides significantly better reproducibility, with a CV value of 11%. We have also determined that this approach provides an improved mass range over 2D-PAGE, allowing the characterization of high-molecular weight cytoskeletal proteins degraded following TBI, and that more differential protein targets are identified by this approach compared with 2D-PAGE. A detailed characterization of the approach has been published (**Ottens et al., Analytical Chemistry 2005** and **Wang et al., Expert Reviews in Proteomics 2005**).

We have since applied our new differential proteomics approach to biomarker discovery for TBI (**Kobeissy et al., Molecular and Cellular Proteomics 2006**) and brain ischemia (**Ottens et al., paper in preparation 2006**). We identified 38 proteins with increased and 21 proteins with decreased abundance following TBI. Using our middle cerebral arterial occlusion (MCAo) model of ischemic stroke, we identified 24 proteins with increased and 54 proteins with decreased abundance following injury. Only 11 proteins common between the two studies showed similar trends in abundance changes, while 3 proteins appeared to react oppositely between the two injury paradigms. All of these proteins are putative biochemical markers of neurotrauma. We have selected nine proteins from the TBI study for secondary validation by Western blot analysis, and found that all demonstrated the expected abundance change and/or proteolytic degradation following injury. We are currently in the process of validating approximately 15 of the differential proteins from the MCAo study.

We have also integrated a second proteomics approach to biomarker discovery, as no single approach is capable of identifying all protein changes. In this approach, control and injured tissue lysate

is applied separately to a panel of antibodies call a Power Blot® (BD Biosciences). The approach is a high-throughput immunoblotting (HTPI) technique that rapidly assesses protein changes in a similar manner to Western blot analysis, but for 1000 proteins simultaneously (**Figure 3**). With this approach we identified 9 proteins with increased and 48 proteins with decreased abundance following TBI (**Liu et al., Biochemical Journal 2006**). In this study, we also characterized the proteolytic products (the degradome) of calpain-2 and caspase-3 following *in vitro* digestion of naïve tissue. Superimposed, the data sets indicated that 42 of the 48 decreased proteins were also degraded by calpain-2 or caspase-3. This would suggest that a large percentage of proteomic changes following TBI are related to proteolysis, in line with our previous research findings on targeted proteins (e.g., alphaII-spectrin). The HTPI approach has also been applied to ischemic injury, to be presented in a manuscript in preparation by our WRAIR collaborators




Figure 3. Post-TBI protein degradation as observed by BD PowerBlot panel. Two proteins, β II-spectrin and KNP-1, are shown degraded at 2 days following TBI. Blots were prepared with 200 μ g of Naïve and 48hr TBI cortical tissue lysates. The BD Science PowerBlot is a high-throughput screening technology based on the specific nature of an antibody library. In this proposal, similar blots will be customized with antibodies specific to brain substrates of TBI-relevant protease, to observe and quantify breakdown products (BDP) at multiple post-injury time points with respect to naïve tissue.

The identification of proteolytic breakdown products has been a reoccurring theme for this project. We have been working with a number of TBI biomarkers that show degradation following injury, including map-tau, microtubual associated protein 2 (MAP2), alphaII-spectrin and myelin basic protein (MBP). We have recently published our findings on MBP (**Liu et al., J. Neurochemistry 2006**) and have demonstrated for the first time that MBP is cleaved by calpain. We also demonstrated that this is a dominant cleavage event following TBI. We are in the processes of developing assays for MBP breakdown products in CSF. We have also expanded our scope of proteolytic processing following TBI to include caspase-7 proteolysis (**Larner et al., J. Neurochemistry 2005**). We have demonstrated for the first time that caspase-7 is activated in the brain following TBI in rats. We continue to explore the difference in substrates between caspase-7 and the dominant caspase-3, as we anticipate that any developed therapy that might inhibit apoptosis induced caspase-3 may also have to inhibit caspase-7, which may be an alternative route for protein degradation.

SOW 1: PROTEOMICS-BASED DEVELOPMENT OF ANTIBODY CHIP ARRAY

Final CAX-PAGE / RPLC-MSMS format

Multidimensional Biomarker Discovery Platform




Figure I. Schematic of non-targeted proteomics analysis for biomarker discovery. Tissue will be processed to extract proteins into solution and clarify out particulates while abundant proteins will be removed from CSF. These samples are resolved by multidimensional protein separations. Differential proteins are selected and trypsinized for peptide analysis by LC/MSMS. Peptide data is then analyzed (bioinformatics) to identify the differential protein and confirm differential abundance.

This platform is now fully published in Kobeissy, F.H., Ottens, A.K., Zhang, Z.Q., Dave, J.R., Tortella F.C., Hayes, R.L. Wang, K.K.W. (2006) Differential proteomic analysis of traumatic brain injury biomarker study using CAX-PAGE/RPLC-MSMS method. *Mo. Cell. Proteomics* 5, Oct;5(10):1887-1898.

The same platform was further applied to MCAO model for ischemic brain injury biomarker discovery:




Figure II. Fold-change of differential proteins following surgically induced cortical ischemia (MCAO model).




Figure III. Classification of post-ischemia differential proteins, and percentage of total number of differential proteins.

This work is being prepared for peer-reviewed journal submission :

Ottens, A.K., Wang, K.K.W. , Hayes, R.L. May, L., Tortella F.C., Dave J.R., (2006) Differential proteomic analysis of focal ischemic brain injury biomarker study using CAX-PAGE/RPLC-MSMS method. ***In preparation (Mol. Cell Proteomics)***

Similarly, a more detailed quantitative MS-based analysis of demyelination biomarker MBP isoform and fragments is submitted for publication:

Ottens,A.K. et al. Hayes, R.L. Wang K.K.W. Quantitative Mass spect analysis of MBP isoforms and breakdown products after TBI in rat. **Submitted.**

For antibody array array work in SOW1B, we have completed high throughput immunoblotting (HTPI) analysis of rat MCAO tissue vs. sham control. See representative data.




Figure IV . Example of MCAO (ischemia) vs Sham HTPI data. MCAO (24 h ischemia) injured cortex (upper panel) was compared to that of sham control cortex (lower panel). Molecular weight markers (lane 40) are indicated on the right. Ten proteins were reduced in abundance (blue boxes) while 12 had increased (red boxes).

This work has been written up as full manuscript and submitted for publication :

Yao, C.P., Williams, A.J., Lu, M., Chen, R., Ottens, A.K., **Wang, K.K.W.**, Hayes, R.L. Frank C. Tortella and Jitendra R. Dave (2007) High-throughput immunoblotting for detection of protein biomarkers following focal ischemic or penetrating ballistic-like brain injuries in rats. Submitted 1-23-2007.

SOW 2: ANALYSES OF UTILITY OF BIOMARKERS (CSF)

Most importantly, using a combined high throughput immunoblotting (HTPI) and the CAX-PAGE-RPLC-MS/MS methods applied to both the non-penetrating traumatic brain injury (TBI) (Controlled cortical impact; CCI) and ischemia (middle cerebral artery occlusion; MCAO) models; we have yielded a list of candidate protein biomarkers. (**Table I**). These markers cover a various vulnerable cellular targets (neurons, glia, myelin, and microglia) or subcellular structures (axons, dendrites, cell body, and synaptic terminal) (**Figure A**) Interestingly, most of these markers identified have been in more than one of the four paradigms used, further validating the robustness of these findings. In addition, many markers are proteolytically modified; consistent with destructive tissue proteolysis we have observed previously (Wang 2000). All of these potential markers can be detected in tissue or CSF either by quantitative immunoblotting or ELISA (**Table I**). In addition, we have now established ELISA assays for the two key alphaII-spectrin breakdown products (SBDP145 generated by calpain , mainly in necrosis) and SBDP120, generated in caspase during apoptosis. These markers can be further validated using rat CSF and serum samples (see **Figure C below**) We submit that these candidate markers listed in Table I are also potential biomarkers of PBBi and this hypothesis will be tested in the work described in SOW1b.

Table I: Candidate Brain Injury Biomarkers identified with different proteomic methods

Biomarker identified	Identification Proteomic Methods	Location	Quantitative Immunoblotting	ELISA
Spectrin-BDP145 kDa (SBDP145)	TBI-HTPI, MCAO- CAX-PAGE, MCAO- HTPI	Axon-necrosis	Yes	Yes
Spectrin-BDP120 kDa (SBDP120)	TBI-HTPI, MCAO- CAX-PAGE, TBI-CAX-PAGE	Axon-apoptosis	Yes	Yes
MBP-BDP	TBI-HTPI,	Myelin	Yes	Yes
Synaptotagmin-BDP	TBI-HTPI, TBI-CAX-PAGE	Pre-synaptic terminal	Yes	In progress
Tau-BDP	MCAO- HTPI	Axons	Yes	In progress
UCH-L1	TBI-CAX-PAGE	Neuronal cell body	Yes	Yes
EMAP-II	MCAO- HTPI	Microglia	Yes	
Collybistin	MCAO- HTPI	Neuronal cell membrane	Yes	
GAPDH	TBI-CAX-PAGE	Cell body / Nucleus	Yes	In progress
CRMP-2	TBI-CAX-PAGE	Axons / Dendrites	Yes	In progress
NP25	TBI-CAX-PAGE	Cell body	Yes	In progress
GFAP	TBI-HTPI,	Blood Brain Barrier	Yes	Yes
MAP2	MCAO- CAX-PAGE, TBI-CAX-PAGE MCAO- HTPI	Dendrites	Yes	In progress
Protein phosphatase-2A α	MCAO-CAX-PAGE	Cell body	In progress	




Figure A. Panel of candidate brain injury biomarkers.

Rat CSF samples (7-20 μ l) and different amounts of biomarker protein standards (SBDPs and UCH-L1, etc.; whenever available) will be subjected to Western blot analysis employing techniques routinely used in our laboratories). For example, primary antibodies used are mouse anti- α II-spectrin (Affiniti, Cat#.FG6090) or rabbit anti-UCH-L1 (Chemicon Cat#.AB1761). Semi-quantitative evaluation of protein

and BDP levels will be performed via computer-assisted densitometric scanning (Epson XL3500 high resolution flatbed scanner) and image analysis with Image-J software (**Figure B**).




Figure B. UCH-L1 levels are also elevated in rat CSF after ischemia (MCAO)

This work is now written up for poster presentation and full paper submission:

Liu, M.C., Zheng, W.R., Akle, V., Papa, L., L. Akinyi, Oli, M. and **Wang, K.K.W.** (2006) UCH-L1 is neuro-specific biomarker for ischemic and traumatic brain injury in rats. In prep.

SOW 3. IDENTIFYING BIOMARKERS OF TBI AND ISCHEMIA IN BLOOD

ELISA Assays of TBI and Ischemia (MCAO) Biomarkers: We have previous successes in biomarker ELISA development. For example, for aII-spectrin, fragment-specific (SBDP145, SBDP120) sandwich ELISA have been constructed and have sub-ng/mL sensitivity (**Figure C**). Similarly UCH-L1 SW-ELISA also developed (**Figure D**) and validated in rat TCAO biofluids (CSF and serum) (**Figure E, F**). ELISA for other already identified (**Table 1**) or novel candidate PBBI biomarkers (from SOW1) will be developed and optimized with similar method.





Figure C. SBDP145 sandwich ELISA configuration.



Dotted lines indicate where rat serum samples fall on the curve.

Figure D. UCH-L1 sandwich ELISA standard curve.




Figure E. SBDP145 levels are elevated in CSF and serum after TBI in a rat model. 1.0 mm compression = moderate TBI; 1.6 mm compression = severe TBI.





Figure F. SBDP145: CSF and serum levels after 30 min and 2 h MCAO in rats

Lastly, EMAP-II identified as a potential biomarker of distinguishing ischemic vs. penetrating traumatic brain injury (PBBI). Its levels are reduced in CSF after MCAO, but elevated after PBBI (**Figure G**). It was further validated to be elevated in with human TBI CSF and serum (**Table II**).



The EMAP II Ab from Transduction Laboratories Cat# 14720.

Figure G. p43/EMAP II expression in CSF at 6-24h post MCAO /PBBI

Table II is ELISA data showing EMAPII levels were elevated in CSF (a) and serum (b) in human patient suffering from traumatic brain injury, when compared to uninjured controls. In addition, EMAPII levels in pooled CSF and serum samples from TBI patients at some time points were also elevated when compared to those in pooled uninjured controls.

Table II,

(a)	Human CSF samples	[EMAPII] ng/mL
	pooled Control	0.000
	pooled TBI /0h	0.000
	pooled TBI/24h	0.000
	pooled TBI /48h	0.000
	pooled TBI /72hr	0.306

pooled TBI /96hr	0.000
#16/0hr	0.334
#16/12h	1.077
#16/24h	1.471
#16/48h	0.687
#16/72h	0.509
#16/120h	0.008
#16/168h	0.000
#34/24h	0.300
#34/48h	0.000
#34/72h	0.002
#34/168h	0.000

(b)	Human serum samples	[EMAPII] ng/mL
	pooled Control	0.059
	pooled TBI/ 0 h	0.133
	pooled TBI/ 48h	0.043
	pooled TBI/ 72hr	0.163
	pooled TBI/ 96h	0.000
	#16/0h	0.902
	#16/12h	0.160
	#16/120h	0.178
	#16/72h	0.064
	#16/168h	0.240
	#34/0h	0.045
	#34/12hr	0.204

KEY RESEARCH ACCOMPLISHMENTS

- Following up on original work done in TBI, we have confirmed that breakdown products of α II-spectrin are also released into the cerebrospinal fluid (CSF) of rats following MCAO.
- We have initiated studies to confirm that biochemical markers of TBI are associated with varying magnitudes of injury, including lesion volume.
- We have summarized the application of proteomics technologies for studies of acute brain injury in a peer reviewed publication.
- We have developed an effective integrated proteomics-based research platform that was an essential and necessary goal of the first year of funding. This platform can be extended to penetrating ballistic brain injury and other indicators.
- We have provided the first systematic preclinical confirmation of a biochemical marker of TBI confirming that such markers can be reliably associated with varying magnitudes of injury including lesion volume.

- We have published the first characterization of a comprehensive and successful proteomics-based platform to discover novel biomarkers of TBI.
- We have made significant advances in methodologies facilitating rapid discovery of potential protein biomarkers of TBI.
- We have expanded our effort to identify new proteolytic markers of TBI incorporating studies of cathepsins in addition to ongoing studies of calpain proteolysis.
- We have developed a novel platform for differential proteomics and have applied it to biomarker discovery in TBI and MCAo.
- We have reported the first use of high-throughput Immunoblot analysis for biomarker discovery in TBI and MCAo.
- We have validated the differential behavior of 9 TBI markers discovered with our proteomics technology and are in the process of validation upwards of 15 ischemia markers.
- We have characterized new proteolytic markers of TBI to include myelin basic protein and mappau.
- We have expanded our efforts in studying proteolytic processing following TBI by incorporating studies of caspase-7.
- We have developed ELISA biomarker assays for at least five biomarkers and validated at least four markers (SBDP145, SBDP120, UCH-L1 and EMAPII) in animal/human biofluids (CSF, serum) after brain injury.

REPORTABLE OUTCOMES

Publications

N. Denslow, M.E. Michel, M.D. Temple, C.Y. Hsu, K. Saatman and **R.L. Hayes**. Application of proteomics technology to the field of neurotrauma: Report from the human proteome project meeting. *J. Neurotrauma* 20(5): 401-407, 2003.

Brian R. Pike, Jeremy Flint, Jitendra R. Dave, X.-C. May. Lu, Kevin K.W. Wang, Frank C. Tortella and **Ronald L. Hayes**. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived VII-spectrin in CSF after middle cerebral artery occlusion in rats. *JCBFM*, 24(1): 98-106, 2004.

Jose A. Pineda, Kevin K.W. Wang, Ronald L. Hayes. Biomarkers of proteolytic damage following traumatic brain injury. *Brain Pathology*, 14(2): 202-209, 2004.

NC Ringger, BE O'Steen, JG Brabham, X Silver, J Pineda, KKW Wang, RL Hayes. A novel biomarker for traumatic brain injury: CSF alpha-II-spectrin breakdown product levels are associated with injury magnitude and predict lesion size. *J Neurotrauma*, 21(10): 1443-1456, 2004.

Wang KKW, Ottens AK, Haskins WE, Liu MC, Kobeissy F, Denslow ND, Chen S, **Hayes RL**. Proteomics studies of traumatic brain injury in *International Review of Neurobiology*, Vol. 62, Human Brain Proteome. Neubold EL, Ed. Elsevier, New York, 2004, pp 215-340.

William Haskins, Firas H. Kobeissy, Regina A. Wolper, Andrew K. Ottens, Jason W. Kitlen, Scott H

McClung, Barbara E. O'Steen, Marjorie M. Chow, Jose A. Pineda, Nancy D. Denslow, **Ronald L. Hayes**, Kevin KW Wang. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. (J Neurotrauma, 22(6): 629-644, 2005.

Rebecca C. Ellis, J. Nicole Earnhardt, **Ronald L. Hayes**, Kevin K.W. Wang and Douglas K. Anderson. Cathepsin B mRNA and protein expression following contusion spinal cord injury. J. Neurochem, 88:689-697, 2004.

Ottens AK, Kobeissy FH, Wolper RA, Haskins WE, Hayes RL, Denslow ND, Wang KKW. A Multidimensional Differential Proteomic Platform Using Dual Phase Ion-Exchange Chromatography - Polyacrylamide Gel Electrophoresis / Reverse Phase Liquid Chromatography Tandem Mass Spectrometry. *Anal. Chem.* 2005, 77:4836-4845.

Haskins WE, Kobeissy FH, Wolper RA, Ottens AK, Kitlen JW, Liu MC, McClung SH, Lundberg AG, O'steen BE, Chow MM, Pineda JA, Denslow ND, Hayes RL, Wang KKW. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry, *J. Neurotrauma* 2005, 22:629-644.

Wang KKW, Ottens AK, Liu MC, Lewis SB, Meegan C, Oli MW, Tortella FC, Hayes RL. Proteomic identification of biomarkers of traumatic brain injury. *Expert. Rev. Proteomics* 2005, 2:603-614.

Larner SF, McKinsey DM, Hayes RL, Wang KKW. Caspase-7: Increased expression and activation following traumatic brain injury in rats. *J. Neurochem.* 2005, 94:97-108.

Liu MC, Akle V, Zheng WR, Dave JR, Tortella FC, Hayes RL, Wang KKW. Comparing calpain- and caspase-3-degradation patterns in traumatic brain injury by differential proteome analysis. *Biochem. J.* 2006, 394:715-725.

Liu MC, Kitlen J, O'Steen B, Flint J, Dave JR, Tortella FC, Hayes, RL, Wang KKW. Extensive myelin basic protein degradation in rat brain after traumatic brain injury. *J. Neurochem.* 2006, 98:700-712.

Kobeissy, F.H., Ottens, A.K., Zhang, Z.Q., Dave, J.R., Tortella F.C., Hayes, R.L. Wang, K.K.W. (2006) Differential proteomic analysis of traumatic brain injury biomarker study using CAX-PAGE/RPLC-MSMS method. *Mo. Cell. Proteomics* 5, Oct;5(10):1887-1898.

Pineda, J., Liu, M.C., Aikman, J., Akle, V., Lewis, S., Wang, K.K.W., Robertson, C., Hayes, R.L. (2007) Clinical significance of α II-Spectrin Breakdown Products in CSF after Severe Traumatic Brain Injury in Human. *J. Neurotrauma*; 24: 354 -366.

In Submission / In preparation:

Ottens, A.K., Wang, K.K.W. , Hayes, R.L. May, L., Tortella F.C., Dave J.R., (2006) Differential proteomic analysis of focal ischemic brain injury biomarker study using CAX-PAGE/RPLC-MSMS method. *In preparation.*

Ottens,A.K. et al. Hayes, R.L. Wang K.K.W. Quantitative Mass spect analysis of MBP isoforms and

breakdown products after TBI in rat. *Submitted.*

Yao, C.P., Williams, A.J., Lu, M., Chen, R., Ottens, A.K., Wang, K.K.W., Hayes, R.L. Frank C. Tortella and Jitendra R. Dave (2007) High-throughput immunoblotting for detection of protein biomarkers following focal ischemic or penetrating ballistic-like brain injuries in rats. Submitted 1-23-2007.

Liu, M.C., Zheng, W.R., Akle, V., Papa, L., L. Akinyi, Oli, M. and Wang, K.K.W. (2006) UCH-L1 is neuro-specific biomarker for ischemic and traumatic brain injury in rats. In prep.

Ottens, A.K. and Wang, K.K.W. (Eds.) (2008) "Methods in Neuroproteomics". Methods in Molecular Biology (Series); Humana Press., PA; 18 Chapters

Yao, C.P., Williams, A.J., Lu, M., Chen, R., Ottens, A.K., Wang, K.K.W., Hayes, R.L. Frank C. Tortella and Jitendra R. Dave ENDOTHELIAL-MONOCYTE ACTIVATING POLYPEPTIDE II (EMAP-II), A BIOMARKER FOR USE IN DIAGNOSIS AND TREATMENT OF BRAIN INJURY. US provisional patent application number 60/809,986 filed May 18, 2006.

Abstracts

Ronald L. Hayes & Andrew K. Ottens. Developing proteomics-based platforms to study brain injury: Challenges in data analysis and interpretation. Applied Math Seminar, UF Department of Mathematics, Apr. 2004.

Angileri FF, Aguenouz M. Germano A, Toscano A, deDivitis O, Glusa M, Lewis SB, Wang KKW, Papa L, Pike BR, Newcomb-Fernandez JK, Hayes RL, Pineda J, Vita G, d'Avella D, Tomasello F. Detection of α II-spectrin and breakdown products in humans after severe traumatic brain injury. Society for Academic Emergency Medicine, May 2004.

Andrew K Ottens, Firas H Kobeissy, Zhiquan Zhang, Erin Golden, Regina Wolper, Su-Shing Chen, Ming Chen Liu, Ronald L Hayes, Kevin KW Wang. The bioinformatic challenge in brain injury neuroproteomics. Bioinformatics Workshop, 2004.

S Sadasivan, RC Ellis, W O'Steen, MC Liu, RL Hayes, D Anderson, KKW Wang. Concurrent proteolysis of axonal α II-spectrin and myelin basic protein following spinal cord injury. 10th Annual Kentucky Spinal Cord & Head Injury Research Symposium, June 2004.

Kevin KW Wang, Nancy D Denslow & Ronald L Hayes. Applying proteomics in brain injury studies. International Neurotrauma Symposium (INTS), September 2004.

JA Pineda, JM Aikman BE O'Steen, EA Johnson, KK Wang, J Flint and RL Hayes. α II-spectrin and severity of injury after controlled cortical impact in the immature rat brain. INTS, Sept. 2004.

Jitendra R Dave, Changping Yao, Anthony J Williams, XiChun M Lu, Ren Wu Chen, Rebecca Whipple, Rebecca Connors, Kevin KW Wang, Ronald L Hayes and Frank C Tortella. Penetrating brain injury in the rat: VII proteomics-based identification of protein expression. INTS., Sept. 2004.

AK Ottens, EC Golden, MC Liu, R Wolper, ND Denslow, RL Hayes, KKW Wang. Quantitative degradomic mass spectrometry approach to monitoring myelin basic protein proteolysis resulting from TBI. SFN, Oct. 2004.

FH Kobeissy, AK Ottens, R Wolper, ZQ Zhang, RL Hayes, ND Denslow, KKW Wang. Utilizing an innovative and powerful multidimensional separation scheme for neuroproteomics analysis. SFN, Oct. 2004.

Wenrong Zheng, Ming Cheng Liu, Ronald L Hayes, Kevin KW Wang. Simultaneous breakdown of α II- and β II-spectrin by calpain and caspase-3 in rat cerebrocortical culture under oncotic, apoptotic and excitotoxic challenges. SFN, Oct. 2004.

Ming Cheng Liu, Wenrong Zheng, B O'Steen, Ronald L Hayes and Kevin KW Wang. Degradation of β II-spectrin in rat brain after traumatic brain injury. SFN, Oct. 2004.

SL Janssen, RL Hayes, MS Gold, KKW Wang. α II-spectrin and β II-spectrin breakdown in PC12 cells after alcohol treatment. SFN, Oct. 2004.

Wenrong Zheng, Ming Cheng Liu, Ronald L Hayes, Kevin KW Wang. Simultaneous breakdown of α II- and β II-spectrin by calpain and caspase-3 in rat cerebrocortical culture under oncotic, apoptotic and excitotoxic challenges. NNS, Oct. 2004.

SI Svetlov, KKW Wang, RL Hayes. Oligomerization of cannabinoid receptors as a pathogenic marker of TBI. NNS, Oct. 2004.

Ronald L. Hayes. An integrated platform for discovery and preclinical/clinical validation of biomarkers of brain injury. CHI Biomarker Validation meeting, San Francisco, Feb. 2005.

Linda Papa, Jose Pineda, Steve Lewis, Kevin Wang, Jason Demery, Shelley Heaton, Joe Tepas and Ronald Hayes. Levels of alpha-II spectrin breakdown products in human CSF and outcome after severe traumatic brain injury. Society for Academic Emergency Medicine, May, 2005.

Changping Yao, Anthony J Williams, X-C May Lu, Renwu Chen, Zhilin Liao, Rebeca Connors, Kevin K Wang, Ron L Hayes, Frank C Tortella, Jitendra R Dave. High throughput immunoblot analysis of differential protein expression in rat brain tissues following penetrating or ischemic brain injuries. European Neurological Society. Abstract for poster at the 2005 meeting.

KW Wang, Ronald L Hayes. Identification and assessment of clinical validity of biomarkers of severe traumatic brain injury: Implications for clinical trial design. BMBD, Sept, 2005.

Ronald L. Hayes. Identification of novel biomarkers to assess injury severity, outcome and therapeutic efficacy following TBI. AAPMR, Oct. 2005.

Jose Pineda, Ronald L. Hayes, et al. Clinical validation of alphaII-spectrin breakdown products as a biomarker of severe TBI: a pilot study. NNS, 2005.

Kevin KW Wang, Firas H Kobeissy, Ronald L. Hayes, Andrew K. Ottens. Differential proteomic analysis of TBI biomarker study. Conference on Data Mining, Systems Analysis and Optimization in Neuroscience. University of Florida, Feb, 2006.

Ronald L. Hayes. Biochemical markers of brain injury: An integrated proteomics-based

approach. DoD Military Health Research Forum. San Juan, Puerto Rico, May 2006.

Changping Yao, Anthony J Williams, X-C May Lu, Renwu Chen, Zhilin Liao, Rebecca Connors, Kevin K.W. Wang, Ronald L. Hayes, Frank C Tortella and Jit R. Dave. EMAP II: A potential biomarker for discriminating traumatic vs. ischemic brain injury. INTS, The Netherlands, May, 2006.

RL Hayes, JA Pineda, SB Lewis, AB BALadka, L Papa, HJ Hannay, S Heaton, MC Liu, JM Aikman, V Akle, J Demery, G Brophy, JJ Tepas, KKW Wang, CS Robertson. Clinical Studies of Biomarkers in Severe TBI. INTS, The Netherlands, May 2006.

C Robertson, G Brophy, L Papa, J Pineda, RL Hayes. Biomarker kinetics in the CSF of TBI patients. NNS, 2006.

C Yao, AJ Williams, SCM Lu, R Chen, Z Liao, RA Connors, KKW Wang, RL Hayes, FC Tortella and JR Dave. Differential expression of protein EMAP II precursor following ischemic or TBI in rat. Society for Neuroscience (SFN), 2006.

Ronald L Hayes. Concurrent concepts in biomarkers of neurotrauma. 7th Annual UC Neurotrauma Meeting, Aug, 2006.

Papa L, Hayes RL, Robertson C, Pineda J, Lewis S, Demery J, Heaton S, Tepas JJ, Akle V, Zheng WR, Liu MC, Akinyi L, Robinson G, Wang KKW, Oli MW. Levels UCH-L1 in human CSF and severity of injury following severe TBI. Annual Emergency Medicine Conference, Chicago, May 2007.

Christopher Cox, Ming Chen Liu, Kevin Wang, Ronald L. Hayes, Bruce G. Lyeth. Biomarker and histologic study of M1-selective anticholinergic treatment in rat fluid percussion brain injury. NNS, July 2007.

Ming Cheng Liu, Monika K Oli, Linnet Akinyi, Wenrong Zheng, Firas Kobeissy, Linda Papa, Jitendra R. Dave, Frank C Tortella, Ronald L Hayes & Kevin KW Wang. Ubiquitin-C terminal hydrolase as a biomarker for ischemic and TBI. NNS, July 2007.

Gillian Robinson et al., BANDITS: A novel clinical platform to validate the utility of potential brain injury biomarkers. NNS, July 2007.

AK Ottens, L Bustamante, EC Golden, RL Hayes, KKW Wang, FC Tortella, JR Dave. Biomarkers of neurotrauma comparing the neuroproteome of ischemic and concussive injuries. NNS, July 2007.

Wang KK, Kobeissy FH, Ottens AK, Zhang Z, Liu MC, Denslow ND, Dave JR, Tortella FC, Hayes RL. Multidimensional separation-coupled tandem mass spectrometry platform for rapid discovery of putative protein biomarkers for TBI. NNS, July 2007.

Ming Cheng Liu, Monika Oli, Linnet Akinyi, Wenrong Zheng, Firas Kobeissy, Linda Papa, Jitendra R Dave, Frank C Tortella, Ronald L Hayes, Kevin KW Wang. A novel protein biomarker for acute brain injury biomarker: Ubiquitin-C terminal hydrolase (UCH-L1). SFN, November 2007.

Oral Presentations

Award Recipient and Invited Speaker, Lance Award Ceremony, Charlotte, NC

Conference Attendee, Critical Care Congress, Orlando, FL
Invited Attendee, CHI's Utilizing Biomarkers in Diagnostic Research conference, San Francisco, CA
Invited Speaker, Applied Math Seminar, Dept. of Mathematics, UF-Gainesville
Invited Participant, Molecular Diagnostics Conference, CHI sponsored, San Francisco, CA
Invited Speaker, Grand Rounds, Univ of Mississippi Dept Neurosurgery, Jackson, MS
Invited Speaker & Poster Presentation, DoD Peer Review Medical Research Program Meeting, San Juan, Puerto Rico
Invited Speaker, Brain Injuries Conference, Tampa, FL
Invited Speaker, Kentucky Spinal Cord & Head Injury Research Symposium, Lexington, KY
Invited Speaker, ROSE 20th Annual Seminar, Minneapolis, MN
Invited Speaker, Combine ATACCC & NATO Meetings, St. Petersburg, FL
Invited Speaker, ACRM-ASNR Joint Conference, Ponte Vedra, FL
Attendee, Congress of Neurological Surgeons, San Francisco, CA
Attendee, National Neurotrauma Society Annual Meeting, San Diego, CA
Invited Panelist, CHI's Translational Research conference, San Francisco CA (Feb)
Invited Speaker, VA Sponsored TBI Workshop, WRAMC, Silver Spring, MD
Invited Speaker, 3rd Pannonian Symposium on CNS Injury, Pecs, Hungary
Invited Lecturer, Fondazione Santa Lucia, Rome, Italy
Invited Speaker, National Chinese Academy Workshop on Cranial Cerebral Trauma, Shanghai, China
Co-Organizer and Plenary Speaker, 4th International Conference on Biochemical Markers for Brain Damage (BMBD), Boothbay Harbor, ME
Invited Speaker, North American Brain Injury Society Medical-Clinical Conference, Amelia Island, FL
Invited Speaker, National Brain Injury Research, Treatment, Training Foundation Conference, Johnstown, PA
Invited Speaker, American Academy of Physical Medicine & Rehabilitation, 2005 Annual Assembly, Philadelphia PA
Invited Speaker, Join DoD/Academic Funding Initiative Forum, University of Toronto, Canada
Invited Attendee and Session Discussant Leader, DoD DARPA Predicting Health & Disease Workshop, Annapolis MD

CONCLUSIONS

In conclusion, this proposal has established the first proteomics based program to identify biochemical markers of acute brain injury. We have successfully integrated cutting edge technologies to identify a large number of novel biomarker that can provide important information on the magnitude and mechanisms of injury produced by brain ischemia and trauma. We have also initiated efforts to refine assays that allow sensitive and quantitative detection of biomarkers. This powerful research platform is now being extended to develop biomarkers for penetrating ballistic brain injury and blast induced brain injury. The research recorded here was instrumental in initiating supporting studies that lead to the BANDITS program to develop a fieldable device to detect brain injury in combat environments. We strongly believe our efforts will have important impact on medical practice in the next few years.